Luveltamab Tazevibulin (STRO-002) is a medication being studied for its effectiveness and safety in treating women with relapsed platinum-resistant epithelial ovarian cancer. This type of cancer can also include cancers of the fallopian tube or primary peritoneal cancers. The medication targets cancer cells that express a specific protein called folate receptor alpha (FOLR1), which is often found in these types of cancers. The goal is to see if this medication can help control the cancer better than standard chemotherapy options.

Investigator’s Choice Chemotherapy refers to the standard chemotherapy treatments that doctors can choose from based on their experience and the specific needs of the patient. These treatments are commonly used to manage ovarian cancer that has not responded well to platinum-based chemotherapy. The study compares the effectiveness of these standard treatments with the new medication, Luveltamab Tazevibulin, to see which works better for patients.

Advanced Epithelial Ovarian Cancer – This is a type of cancer that begins in the cells on the surface of the ovary. It can also include cancers that originate in the fallopian tubes or the peritoneum, which is the lining of the abdominal cavity. The disease is characterized by the uncontrolled growth of abnormal cells that can spread to other parts of the body. As it progresses, it may cause symptoms such as abdominal bloating, pelvic pain, and changes in bowel habits. The cancer often spreads to nearby tissues and organs, making it more challenging to manage. It is typically diagnosed at an advanced stage due to the subtlety of early symptoms.